Rizatriptan benzoate-loaded dissolving microneedle patch for management of acute migraine therapy.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Sage Publications Country of Publication: England NLM ID: 8813912 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1530-8022 (Electronic) Linking ISSN: 08853282 NLM ISO Abbreviation: J Biomater Appl Subsets: MEDLINE
    • Publication Information:
      Publication: 2002- : London : Sage Publications
      Original Publication: Lancaster, PA : Technomic Pub. Co., Inc., [c1986-
    • Subject Terms:
      Drug Delivery Systems* ; Migraine Disorders*/drug therapy ; Triazoles* ; Tryptamines*; Humans ; Skin ; Administration, Cutaneous ; Needles
    • Abstract:
      In this study, dissolving microneedles (MNs) using polyvinyl alcohol (PVA) and poly (1-vinylpyrrolidone-co-vinyl acetate) (P(VP-co-VA)) as matrix materials were developed for transdermal delivery of rizatriptan benzoate (RB) for acute migraine treatment. In-vitro permeation studies were conducted to assess the feasibility of the as-fabricated dissolving MNs to release RB. Drug skin penetration were tested by Franz diffusion cells, showing an increase of the transdermal flux compared to passive diffusion due to the as-fabricated dissolving MNs having a sufficient mechanical strength to penetrate the skin and form microchannels. The pharmacological study in vivo showed that RB-loaded dissolving MNs significantly alleviated migraine-related response by up-regulating the level of 5-hydroxytryptamine (5-HT) and down-regulating the levels of calcitonin gene-related peptide (CGRP) and substance P (SP). In conclusion, the RB-loaded dissolving MNs have advantages of safety, convenience, and high efficacy over conventional administrations, laying a foundation for the transdermal drug delivery system treatment for acute migraine.
      Competing Interests: Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
    • Contributed Indexing:
      Keywords: Microneedles; migraine; rizatriptan benzoate; transdermal drug delivery
    • Accession Number:
      51086HBW8G (rizatriptan)
      0 (Triazoles)
      0 (Tryptamines)
    • Publication Date:
      Date Created: 20240301 Date Completed: 20240404 Latest Revision: 20240404
    • Publication Date:
      20240404
    • Accession Number:
      10.1177/08853282241237323
    • Accession Number:
      38427917